<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1424">
  <stage>Registered</stage>
  <submitdate>27/06/2006</submitdate>
  <approvaldate>29/06/2006</approvaldate>
  <actrnumber>ACTRN12606000266561</actrnumber>
  <trial_identification>
    <studytitle>MACULAR THICKNESS CHANGES FOLLOWING THE USE OF PROSTAGLANDIN ANALOGUES IN PSEUDOPHAKIC PATIENTS</studytitle>
    <scientifictitle>MACULAR THICKNESS CHANGES FOLLOWING THE USE OF PROSTAGLANDIN ANALOGUES IN PSEUDOPHAKIC PATIENTS</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Macular thickness will be evaluated accurately using optical coherence tomography (OCT) in pseudophakic patients using prostaglandin analogues</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Normal eye development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients that underwent uncomplicated cataract surgery will be randomized to use topical bimatoprost 0.03% eye-drop q.d. (n=10), topical latanoprost 0.005% eye-drop q.d. (n=10), or topical travoprost 0.004% eye-drop q.d. (n=10) for 1 month.
Macular thickness will be evaluate using OCT at baseline, 15 days and 1 month.

The baseline will be used as control.</interventions>
    <comparator>No control intervention.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Macular thickness changes after use of prostaglandin analogues in pseudophakic eyes.</outcome>
      <timepoint>At baseline, 15 days and 1 month.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients in the study will be subjects that underwent uneventful cataract surgery with intraocular lens implantation and that have follow-up visits at Ophthalmology Service  Federal University of Uberlândia.Patients were eligible for participation if they met the following inclusion criteria: pseudophakia, uneventful cataract surgery, and visual acuity better than 20/40.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients were excluded from the study if they had a prior history of uveitis or CME, substantial ocular irritation at baseline, or history of intraocular surgery or laser procedure within 4 months before baseline. We also excluded patients who had been treated with PG analogues in the past, and patients who had undergone other ocular surgery except for cataract. Finally, the presence of systemic disorders that could be associated with either uveitis or CME (i.e. diabetes, rheumatologic diseases), pregnancy, lactation or inadequate contraception (in females) were also exclusion criteria.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients will be submitted to optical coherence tomography (OCT) evaluation at baseline and after 15 days and 1 month of treatment. A designated unmasked coordinator – who did not perform any study evaluation or assessment – will receive randomization codes, dispense the medications and instruct the patients on how to use and store the containers.</concealment>
    <sequence>The web program Research Randomizer v3.0 (www.randomizer.org) will be use for random assignment.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>none</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>10/09/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Federal University of Uberlândia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Federal University of Uberlândia</fundingname>
      <fundingaddress />
      <fundingcountry>Brazil</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the protocol is to investigate the effects of prostaglandin analogues on the macular thickness in pseudophakic patients.
Hypothesis: 1) The use of prostaglandin analogues in pseudophakic patients changes the macular thickness  /  2) The use of prostaglandin analogues in pseudophakic patients does not change the macular thickness</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Committee of the Federal University of Uberlândia</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Enyr Saran Arcieri</name>
      <address>Rua Corcovado, n 155 - apto 402
Bairro Patrimônio
Uberlândia - Minas Gerais - Brasil
CEP 38411-092</address>
      <phone>55-34-32559090</phone>
      <fax>55-34-32559090</fax>
      <email>rsaran@triang.com.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Enyr Saran Arcieri</name>
      <address>Rua Corcovado, n 155 - apto 402
Bairro Patrimônio
Uberlândia - Minas Gerais 
CEP 38411-092</address>
      <phone>55-34-32559090</phone>
      <fax>55-34-32559090</fax>
      <email>rsaran@triang.com.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>